title: Evidence for the efficacy of Iniparib, a PARP-1 inhibitor, in BRCA2-associated pancreatic cancer.
abstract: Pancreatic cancer is an aggressive, frequently fatal malignancy that strikes 37,000 patients annually in the U.S.A. It is poorly responsive to standard chemotherapies such as gemcitabine. Approximately 5-10% of pancreatic cancer occurs in the setting of a BRCA2 mutation. Breast and ovarian carcinomas that harbor BRCA2 mutations are susceptible to the effects of an emerging class of targeted agents, namely, poly(ADP-ribose) polymerase (PARP) inhibitors. This report describes the case of a patient with a germline BRCA2 mutation and an associated pancreatic cancer treated with iniparib (BSI-201), a PARP inhibitor, who demonstrated a complete pathologic response to this agent. This case highlights the potential benefit for PARP inhibition in BRCA2-related pancreatic cancer.
authors.affiliation: M.D. Anderson Cancer Center, Houston, TX 77030, USA. dfogelman@mdanderson.org
authors.forename: David R
authors.initials: DR
authors.lastname: Fogelman
authors.forename: Robert A
authors.initials: RA
authors.lastname: Wolff
authors.forename: Scott
authors.initials: S
authors.lastname: Kopetz
authors.forename: Milind
authors.initials: M
authors.lastname: Javle
authors.forename: Charles
authors.initials: C
authors.lastname: Bradley
authors.forename: Isabel
authors.initials: I
authors.lastname: Mok
authors.forename: Fernando
authors.initials: F
authors.lastname: Cabanillas
authors.forename: James L
authors.initials: JL
authors.lastname: Abbruzzese
mesh_terms: D000230:Adenocarcinoma / Q000235:genetics / Q000556:secondary* / Q000628:therapy; D024682:BRCA2 Protein / Q000235:genetics*; D001549:Benzamides / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000235:genetics / Q000473:pathology* / Q000628:therapy; D005260:Female; D018095:Germ-Line Mutation / Q000235:genetics; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000235:genetics / Q000473:pathology* / Q000628:therapy; D010190:Pancreatic Neoplasms / Q000235:genetics / Q000556:secondary* / Q000628:therapy; D000071137:Poly (ADP-Ribose) Polymerase-1; D000067856:Poly(ADP-ribose) Polymerase Inhibitors; D016896:Treatment Outcome
chemical_list: D024682:BRCA2 Protein; C551750:BRCA2 protein, human; D001549:Benzamides; D000067856:Poly(ADP-ribose) Polymerase Inhibitors; C090712:iniparib; C499320:PARP1 protein, human; D000071137:Poly (ADP-Ribose) Polymerase-1